Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000251318 | SCV000302335 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000382905 | SCV000477317 | likely benign | Telangiectasia, hereditary hemorrhagic, type 1 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000858443 | SCV000557847 | benign | Hereditary hemorrhagic telangiectasia | 2024-01-15 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000382905 | SCV000603465 | benign | Telangiectasia, hereditary hemorrhagic, type 1 | 2019-04-13 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001698581 | SCV001916744 | benign | not provided | 2018-12-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392757 | SCV002698201 | benign | Cardiovascular phenotype | 2016-06-16 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001698581 | SCV004010861 | likely benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | ENG: BS2 |